Company / Operating Cash Flow per Share
Neurocrine Biosciences Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$7.87
FY2025
5-year range
$2.74 / $7.87
FY2021-FY2025
Trend
+30.5%
vs FY2024
Sector context
#15 of 210
Health Care
What the data says
Among 210 Health Care companies, Neurocrine Biosciences is in the top 7% for operating cash flow per share. Operating Cash Flow per Share has increased for 9 consecutive years, from $-1.23 in FY2016 to $7.87 in FY2025.
Based on SEC 10-K filings.
7.87 in FY2025 with a 5-year CAGR of +26.0%. Top quartile in the Health Care sector.
Improved from $4.04 to $7.87 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- +30.1%
- 5-Year CAGR
- +26.0%
- 10-Year CAGR
- -
Sector benchmark
+48.6% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's operating cash flow per share has grown for 9 consecutive years.
- In FY2025, operating cash flow per share increased 30.5% year-over-year.
- Ranks #15 out of 210 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.87 | +30.5% |
| FY2024 | $6.03 | +49.3% |
| FY2023 | $4.04 | +13.0% |
| FY2022 | $3.58 | +30.4% |
| FY2021 | $2.74 | +10.8% |
| FY2020 | $2.48 | +52.9% |
| FY2019 | $1.62 | +41.8% |
| FY2018 | $1.14 | +205.2% |
| FY2017 | -$1.09 | +11.8% |
| FY2016 | -$1.23 | -147.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026